Compare Gilead Sciences, Inc. (GILD) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nasdaq100 ETF — how do they compare? Gilead Sciences, Inc. trades at $133.05 (market cap $163.51B), while Nasdaq100 ETF trades at $709.81. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | QQQ | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $746.16 |
52-Week Low | $108.22 | $553.88 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
QQQ trades at $709.87, down 1.36% today amid neutral technical signals. The ETF shows mixed analyst sentiment with a 50/50 buy/sell split among covered analysts. Recent news highlights competitive dynamics with lower-fee alternatives like QQQM and the impact of SpaceX's addition to the Nasdaq-100 index. Technical indicators show the stock trading near key support at $711 with overall neutral momentum.
The outlook remains balanced with exposure to leading tech growth companies but faces headwinds from fee competition and index concentration risks. Upside potential exists through continued AI-driven growth, while downside risks include market volatility and ETF fee pressure. The neutral technical setup suggests near-term consolidation is likely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
